President and CEO of The Critical Path Institute (C-Path) provided testimony and answered questions about drug development yesterday at the Committee on Energy and Commerce’s Subcommittee Hearing on Oversight and Investigations entitled “The Adequacy of FDA Efforts to Assure the Safety of the Drug Supply.”
